Kostarox

Etoricoxib, the active ingredient in Kostarox, is a COX-2 selective NSAID presented as an oral tablet for oral use. It is indicated for the management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout and acute pain in adult patients. GNH USA supplies Kostarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Etoricoxib acts on inflammatory pathways associated with musculoskeletal and crystal‑induced disorders. - Osteoarthritis: reduces joint pain and improves functional mobility. - Rheumatoid arthritis: alleviates inflammatory joint swelling and stiffness. - Ankylosing spondylitis: diminishes spinal pain and improves range of motion. - Acute pain: provides rapid relief of moderate to severe pain episodes. - Gout: decreases pain and inflammation during acute gout flares.

Etoricoxib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal discomfort: dyspepsia, abdominal pain. - Hypertension: elevation of blood pressure. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Cardiovascular thrombotic events: myocardial infarction or stroke. - Severe liver injury: jaundice, elevated transaminases. - Gastrointestinal ulceration or perforation: serious bleeding risk.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors. - Cardiovascular risk: assess history of heart disease or stroke. - Gastrointestinal risk: avoid in patients with active peptic ulcer disease. - Renal function: monitor serum creatinine in those with impaired kidneys. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Drug interactions: review concomitant NSAIDs, anticoagulants and antihypertensives. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Etoricoxib can alter the effect of several co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other COX‑2 inhibitors or non‑selective NSAIDs: additive gastrointestinal toxicity. - ACE inhibitors or diuretics: may reduce antihypertensive efficacy.

Moderate Interactions (Monitor Closely): - Lithium: possible increase in serum lithium levels. - Methotrexate: reduced renal clearance may raise methotrexate exposure.